Resources
[MediRama EDGE] Vepdegestrant (Veppanu): The First FDA-Approved PROTAC-Clinical & Regulatory Insights
- Writer:관리자
- Date:2026-08-27
On May 1, 2026, vepdegestrant (Veppanu) became the first FDA-approved PROTAC therapy, marking a major milestone for targeted protein degradation (TPD) technology.
In this August 2026 lecture, we will explore the development of vepdegestrant, focusing on how PROTAC technology progressed from concept to regulatory approval, its clinical significance, and the key development and regulatory strategies that should be considered to successfully advance future TPD-based therapeutics through clinical development and approval.